A Bayer partner slims down, trimming R&D and enacting layoffs, to better focus on the pair's prostate cancer work

A Bayer partner that co-developed an FDA-approved prostate cancer drug is joining some of its biotech compatriots and taking out its restructuring kit, announcing a swath of R&D changes and warning of potential layoffs Thursday morning.